Business Wire

Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders

Del

Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.

“By joining forces with Vanderbilt University, one of the world’s leading groups integrating basic neuroscience and new translational approaches in neuropsychiatric conditions, Boehringer Ingelheim will strengthen and expand efforts to bring new treatments to patients,” said Bernd Sommer, Ph.D., Global Head CNS Disease Research, Boehringer Ingelheim. “Our colleagues in VCNDD share our strategic vision for drug discovery to regulate maladaptive brain circuitry as the key to alleviate symptoms in neuropsychiatric conditions and bring relief to patients suffering from these debilitating disorders.”

Maladaptive brain circuits are the neurobiological basis of major symptoms in many mental disorders. These symptoms may include memory, concentration and decision-making difficulties as well as social withdrawal, lack of motivation or inability to experience pleasure. Because GPCRs have specific roles in the regulation and modulation of brain circuit functions, these proteins are promising targets for drugs designed to relieve such symptoms. VCNDD has pioneered GPCRs research, yielding a better understanding of their roles in brain modulation.

“We are delighted to partner with Boehringer Ingelheim in developing new treatments for schizophrenia and other major psychiatric disorders,” said P. Jeffrey Conn, VCNDD director. “Boehringer Ingelheim is an industry leader that shares our passion for advancing new therapeutic strategies that could dramatically improve the standard of care for individuals suffering from major mental illness. Through this partnership, we are able to pursue new approaches for correcting deficits in brain circuits that may allow treatment of debilitating symptoms that are not responsive to available medicines.”

Craig W. Lindsley, VCNDD’s director of medicinal chemistry, echoed enthusiasm for the partnership. “The programs partnered with Boehringer Ingelheim represent the culmination of years of basic and translational science within our center and highlight the key role academic drug discovery centers can have on the future of human mental health,” he said.

These new industry-academic collaborations may be the first to focus on the two GPCR targets with a goal to address the unmet medical needs for treatments of cognitive and negative symptoms associated with schizophrenia. The partnership also will enhance the educational goals of VCNDD to train doctoral students and post-doctoral fellows and develop new tools to advance neuroscience knowledge. Further details of the agreement are not disclosed. The present agreements to identify novel therapies for the treatment of neurological conditions are the fifth and sixth agreements between Boehringer Ingelheim and Vanderbilt University, adding to previous agreements focused on the identification of novel therapies for cancer.

About Neuropsychiatric Disorders

Brain or neurological conditions that cause psychiatric symptoms are referred to as neuropsychiatric disorders. The World Health Organization (WHO) reports that neuropsychiatric disorders are the third leading cause of years lived with disability (DALY).1 Moreover, these disorders include mental and behavioral conditions such as depression, anxiety, drug- and alcohol-use disorders, schizophrenia, bipolar disorder and other illnesses2 that together account for 7.4 percent of total global DALYs.3

Please click on the link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/collaboration-vanderbilt-university

Contact information

Media:
Boehringer Ingelheim
Linda Ruckel
Linda.ruckel@boehringer-ingelheim.com
917-692-0848

Vanderbilt University
Heidi Hall
Heidi.Hall@Vanderbilt.edu
615-689-8419

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 15:55:00 CETPressemelding

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 14:29:00 CETPressemelding

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of

Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 14:15:00 CETPressemelding

Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha

Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation22.3.2019 13:00:00 CETPressemelding

Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190322005013/en/ Trueman Man Clinic Network has been successfully completed the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation). The SWITCH Premature Ejaculation Surgery (SWITCH operation) developed in 2010 by Dr. Yang, the chief director of the Trueman Man Clinic Network, can reduce the side effects of penile neurectomy and maintain the stable reduction of the glans sensation. The Trueman Man Clinic Network is the leading hospitals for male enhancement surgeries in Korea consists of 11 clinics, with 16 doctors working. As of 2019, more than 43,000 man clinic surgeries have been performed. (Photo: Business Wire) The Trueman Man Clinic Network is the leading hospitals for m

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible22.3.2019 11:22:00 CETPressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX®▼ (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). “Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical Affairs, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “We are incredibly grateful to the patients and investigators who participated in the MAIA clinical trial programme and look forward to working closely with the regulatory authorities to secure approval of this new combination.” The submission is supported by data from the Phase 3 MAIA (MMY3008) study, which were presented at the 60th Annual Meeting of the American

Bartek Ingredients Expands Leadership Team21.3.2019 22:35:00 CETPressemelding

Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa